[A21-39] Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Last updated 01.07.2021
Commission awarded on 01.04.2021 by the Federal Joint Committee (G-BA).
Adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection
- Stage IIIB/C and IV disease: hint of non-quantifiable added benefit.
- Stage IIIA disease: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.